Recent genome-wide association studies have identified single nucleotide polymorphisms (SNPs) at 7 loci influencing multiple myeloma (MM) risk. We generated expression quantitative trait loci (eQTL) data on malignant plasma cells on 848 patients to fine map the risk loci associations and gain insight into their functional basis. At 7p15.3 the strongest association with MM risk is provided by rs4487645, which is associated with allele-specific cis-regulation of the In this study we analyzed eQTL data generated on malignant plasma cells from 848 MM patients to investigate whether MM risk SNPs influence gene expression in MM cells.
Recent genome-wide association studies have identified single nucleotide polymorphisms (SNPs) at 7 loci influencing multiple myeloma (MM) risk. We generated expression quantitative trait loci (eQTL) data on malignant plasma cells on 848 patients to fine map the risk loci associations and gain insight into their functional basis. At 7p15.3 the strongest association with MM risk is provided by rs4487645, which is associated with allele-specific cis-regulation of the MYC-interacting gene CDCA7L with P-value=4.1x10 -25 . rs4487645 resides within intron 80 of DNAH11 and only 47 kb upstream of the transcription start site of CDCA7L. rs4487645 maps within a binding site for interferon regulatory factor 4 (IRF4) in a strong enhancer element upstream of CDCA7L. IRF4 is a critical transcriptional regulator in B-cell development. Since rs4487645
represents the strongest signal for MM at 7p15.3 the data are compatible with increased expression of CDCA7L being the functional basis of the 7p15.3 association exerting its effects through an extended pathway involving IRF4 and MYC. None of the SNPs were eQTLs specific to cytogenetic subtypes or trans-regulating eQTLs.
GWAS identified SNPs at chromosomes 2p23.3, 3p22. In this study we analyzed eQTL data generated on malignant plasma cells from 848 MM patients to investigate whether MM risk SNPs influence gene expression in MM cells.
Collection of samples and clinico-pathological information from patients was undertaken with informed consent and relevant ethical review board approval in accordance with the tenets of the Declaration of Helsinki. Plasma cells were CD138-purified from bone marrow aspirates as previously published from two case series which had been the subject of a previous GWAS and an additional series of 277 German patients 1,2 . The 665 German MM patients (389 male, mean age 59±9 years) used for eQTL discovery were ascertained through the Heidelberg University probes were discarded). Expression data were normalized using GC-RMA. We excluded genes with log2 expression <3.5 in at least 95% of samples. After QC and confining our analysis to autosomal genes expression data of 9,116 genes was available. The filtered set was analyzed using probabilistic estimation of expression residuals (PEER) to infer broad variance components in the data 8 . For the German analysis batch effect was included as a covariate. PEER was used to adjust expression data for known and hidden intervening variables, such as cytogenetic subgroups. As previously advocated we set the maximum number of unobserved factors (hidden confounders) to 100 or 25% of the case number 7 ; specifically 100 for the German series and 46 for the UK series. PEER computed residuals of expression were used for eQTL analyses. We studied the relationship between MM risk SNPs and expression of genes located within 1 Mb (cis-eQTL analysis) and all other genes (trans analysis) using MatrixEQTL under a linear model 8 . In the case of cis-eQTL analyses on the 7 SNPs and by average 28 genes/SNP we used the Bonferroni adjusted P-value of 0.0003 (0.05/(28x7)= 0.00026). For the detection of trans effects we analyzed the German set using a p-value threshold of 0.05 and tested all identified SNP-gene combinations in the UK data set, considering a joint threshold of P<10-6.
Effect sizes (beta) and standard errors (SE) of eQTLs were calculated using R. Prediction of untyped genotypes was based on data from the 1000 Genomes Project (Phase I integrated variant set release v3) using IMPUTE2 after pre-phasing using SHAPE-IT. Imputed data were analyzed using SNPTEST (v2.5) to account for uncertainties in SNP prediction. Meta analysis was performed using Metal as described 1 .
After quality control expression data on plasma cells were available from 665 patients of the Supplementary Figure 1) . Two other MM risk SNPs showed evidence of eQTL but associations were not significant after adjustment for multiple comparisons (P<0.0003, see Online Methods) -rs1052501 and TRAK1, rs2285803 and HLA-B
and HLA-C (Table 1) . Similarly no significant trans associations were shown after adjustment for multiple testing.
An analysis including imputed and genotyped SNPs located 1Mb each direction from the transcription start site of CDCA7L showed that rs4487645 had the strongest cis effect on the expression of this gene (Table 1 , right columns). According to results of a conditional analysis rs4487645 genotype was sufficient to capture the association between variation at 7p15.3 and CDCA7L expression (Fig 1A, B) . While rs4487645 resides within intron 80 of DNAH11 it is only 47 kb upstream of the transcription start site of CDCA7L. Since DNAH11 is not expressed in malignant plasma cells and rs4487645 represents the strongest signal for MM at 7p15.3 the data are collectively consistent with this eQTL being the functional basis of the association. In the present analysis, rs4487645 did not influence IRF4 expression. IRF4 is a critical transcriptional regulator in B-cell development [11] [12] [13] ; it is expressed in most stages of B-cell developmental and it has critical functions in plasma cell development 14 . Specifically, IRF4 orchestrates pre-B cell development by limiting pre-B cell expansion and by promoting pre-B cell differentiation 15 . IRF4 is an essential gene in MM directing a broad expression program in MM cells; knockdown of IRF4 induces a rapid nonapoptotic cell death in MM cell lines 11, 12 . MYC is a direct target gene of IRF4 through regulation of MYC mRNA levels.
To examine if the risk alleles had different local effects on gene expression in cytogenetic subgroups of MM, we performed eQTL analyses in hyperdiploid, t(4;14) and t(11;14) MM.
Expression data were preprocessed separately for each subgroup using PEER. We could not detect subgroup specific eQTLs. The association between CDCA7L expression and rs4487645 genotype showed no heterogeneity between these subgroups (data not shown).
Major strengths of the present study were that expression data were generated in malignant plasma cells obtained from the same patients on whom GWAS analyses were carried out. Other strengths were the sample size and the availability of two independent sample sets. However, our data may not necessarily fully recapitulate gene expression pertinent in early stages of plasma cell transformation. Additional limitations are that the analysis is restricted to genes for which probes were featured on the Affymetrix array. While most genes within close cis regions were captured by the array it is notable that TERC which is likely a priori to be the basis of the chromosome 3p association was not featured 2 .
In conclusion, our data are consistent with the rs4487645-CDCA7L eQTL being responsible for the chromosome 7p11.2 association with MM risk, probably exerting its effects through an extended pathway involving IRF4, and MYC.
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